Fowler D H, Whitfield B, Livingston M, Chrobak P, Gress R E
Transplantation Therapy Section, Medical Oncology Branch and Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Blood. 1998 Jun 1;91(11):4045-50.
Donor CD8+ T cells capable of host reactivity inhibit marrow graft rejection, but also generate graft-versus-host disease (GVHD). To evaluate whether the Tc1- and Tc2-type subsets of CD8 cells might inhibit rejection without host reactivity, we established an F1 into-parent murine bone marrow transplant model. Donor Tc1 and Tc2 cells were generated that preferentially secreted type I or type II cytokines; both subsets possessed potent cytolytic function, and clonally deleted host-type allospecific precursor CTL in vitro. B6 hosts receiving 950 cGy irradiation did not reject the donor marrow (F1 chimerism of 78.6%; n = 10), whereas hosts receiving 650 cGy rejected the donor marrow (3.8% chimerism; n = 8). At 650 cGy irradiation, the addition of Tc2 cells to the F1 marrow resulted in extensive F1 chimerism (70.8%) in 8 of 8 recipients; in contrast, alloengraftment was not consistently observed in mice receiving Tc1 cells or unmanipulated CD8 cells. Furthermore, when the preparative regimen was further reduced to 600 cGy, only hosts receiving the Tc2-type cells did not reject the F1 marrow. We conclude that Tc2 cells potently inhibit marrow graft rejection without inducing an alloaggressive response and that non-host-reactive Tc2 cells therefore facilitate engraftment across genetic barriers with reduced GVHD.
具有宿主反应性的供体CD8 + T细胞可抑制骨髓移植排斥反应,但也会引发移植物抗宿主病(GVHD)。为了评估CD8细胞的Tc1和Tc2型亚群是否能在无宿主反应性的情况下抑制排斥反应,我们建立了F1代与亲代的小鼠骨髓移植模型。生成了优先分泌I型或II型细胞因子的供体Tc1和Tc2细胞;两个亚群均具有强大的细胞溶解功能,并在体外克隆性清除宿主型同种异体特异性前体CTL。接受950 cGy照射的B6宿主未排斥供体骨髓(F1嵌合率为78.6%;n = 10),而接受650 cGy照射的宿主则排斥了供体骨髓(嵌合率为3.8%;n = 8)。在650 cGy照射下,向F1骨髓中添加Tc2细胞导致8只受体中有8只出现广泛的F1嵌合(70.8%);相比之下,接受Tc1细胞或未处理的CD8细胞的小鼠中未一致观察到同种异体植入。此外,当预处理方案进一步降低至600 cGy时,只有接受Tc2型细胞的宿主未排斥F1骨髓。我们得出结论,Tc2细胞可有效抑制骨髓移植排斥反应而不诱导同种异体攻击反应,因此非宿主反应性Tc2细胞有助于跨越遗传屏障进行植入,并减少GVHD。